



Pfizer Pipeline

As of November 8, 2013



Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of November 8, 2013.
- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

Table of Contents

Pfizer Pipeline Snapshot	4
Cardiovascular & Metabolic Diseases	5
Inflammation & Immunology	6
Neuroscience & Pain	7
Oncology	8
Vaccines	9
Other Areas of Focus (including Biosimilars and Rare Diseases)	10

Pfizer Pipeline Snapshot



Pfizer Pipeline – November 8, 2013

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Cardiovascular and Metabolic Diseases	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Prevention (U.S.)	Registration
	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Treatment	Phase 3
	▶ ertugliflozin (PF-04971729)	SGLT-2 Inhibitor	Diabetes Mellitus-Type 2	Phase 3
	▶ bococizumab (RN316) (PF-04950615)	PCSK9 Inhibitor	Hypercholesterolemia (Biologic)	Phase 3
	PF-00489791	PDE5 Inhibitor	Diabetic Nephropathy	Phase 2
	PF-04634817	CCR2/5 Antagonist	Diabetic Nephropathy	Phase 2
	PF-04937319	Partial Glucokinase Activator	Diabetes Mellitus-Type 2	Phase 2
	PF-05175157		Diabetes Mellitus-Type 2	Phase 1
	PF-05231023		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	PF-06282999		Acute Coronary Syndrome	Phase 1
	PF-06291874		Diabetes Mellitus-Type 2	Phase 1
RN317 (PF-05335810)		Hypercholesterolemia (Biologic)	Phase 1	



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Pfizer Pipeline – November 8, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Inflammation and Immunology	Xeljanz (tofacitinib)	JAK Inhibitor	Psoriasis (Oral)	Phase 3
	Xeljanz (tofacitinib)	JAK Inhibitor	Ulcerative Colitis	Phase 3
	Xeljanz (tofacitinib)	JAK Inhibitor	Psoriatic Arthritis	Phase 3
	anrukinzumab (IMA-638)	IL-13 Inhibitor	Ulcerative Colitis (Biologic)	Phase 2
	PD-0360324	M-CSF Inhibitor	Sarcoidosis, *Lupus (Biologic)	Phase 2
	PF-00547659	MAdCAM Inhibitor	Crohn's Disease, Ulcerative Colitis (Biologic)	Phase 2
	PF-04171327	Selective Glucocorticoid Receptor Modulator	Rheumatoid Arthritis	Phase 2
	PF-04236921	IL-6 Inhibitor	Crohn's Disease, Lupus (Biologic)	Phase 2
	PF-05285401	Multipotent Adult Progenitor Cell	Ulcerative Colitis (Biologic)	Phase 2
	PF-06473871 (EXC 001)	CTGF Inhibitor	Dermal Scarring	Phase 2
	PH-797804	P38 Inhibitor	Chronic Obstructive Pulmonary Disease	Phase 2
	Xeljanz (tofacitinib)	JAK Inhibitor	Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease	Phase 2
	Dekavil		Rheumatoid Arthritis (Biologic)	Phase 1
	PF-03715455		Chronic Obstructive Pulmonary Disease	Phase 1
	PF-04965842		Lupus	Phase 1
PF-06342674		Diabetes Mellitus-Type 1 (Biologic)	Phase 1	



New Molecular Entity

New Indication or
Enhancement

* Note: Additional indications in Phase 1

Pfizer Pipeline – November 8, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Neuroscience & Pain	Celebrex	COX-2	Chronic Pain (U.S.)	Registration
	Remoxy	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain (U.S.)	Registration
	ALO-02 Oxycodone-naltrexone core	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Peripheral Neuropathic Pain	Phase 3
	Lyrica	Alpha-2 Delta Ligand	CR (once a day dosing)	Phase 3
	tanezumab	Nerve Growth Factor Inhibitor	OA Signs and Symptoms (on clinical hold)	Phase 3
	▶ PF-02545920	PDE10 Inhibitor	Huntington's Disease, Adjunctive Treatment for Schizophrenia	Phase 2
	PF-03049423	PDE5 Inhibitor	Stroke Recovery	Phase 2
	PF-04360365 (ponezumab)	Beta Amyloid Inhibitor	Cerebral Amyloid Angiopathy (Biologic)	Phase 2
	PF-05212377 (SAM-760)	5HT6 Antagonist	Alzheimer's Disease	Phase 2
	tanezumab	Nerve Growth Factor Inhibitor	Cancer Pain (Biologic)	Phase 2
	PF-04958242		Schizophrenia	Phase 1
	PF-05089771		Chronic Pain	Phase 1
	PF-05236812 (AAB-003)		Alzheimer's Disease (Biologic)	Phase 1
	PF-06273340		Acute and Chronic Pain	Phase 1
	PF-06305591		Chronic Pain	Phase 1
▶ PF-06412562		Cognitive Disorder	Phase 1	



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Pfizer Pipeline – November 8, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Oncology	dacomitinib (PF-00299804)	pan-HER Inhibitor	Previously Treated Advanced Non-Small Cell Lung Cancer	Phase 3
	dacomitinib (PF-00299804)	pan-HER Inhibitor	1 st Line Non-Small Cell Lung Cancer	Phase 3
	Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant (Asia only)	Phase 3
	inotuzumab ozogamicin	CD22-targeted cytotoxic agent	Acute Lymphoblastic Leukemia (Biologic)	Phase 3
	palbociclib (PD-0332991)	CDK 4,6 Kinase Inhibitor	1 st Line Advanced Breast Cancer, *Cancer	Phase 3
	▶ palbociclib (PD-0332991)	CDK 4,6 Kinase Inhibitor	Recurrent Advanced Breast Cancer	Phase 3
	Sutent	Multiple Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	Xalkori (crizotinib)	c-MET-ALK Inhibitor	ALK-Positive 1st and 2nd Line (supports potential full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer	Phase 3
	dacomitinib (PF-00299804)	pan-HER Inhibitor	Cancer	Phase 2
	Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Liver Cancer	Phase 2
	▶ PF-03446962	ALK1 Inhibitor	2 nd Line Hepatocellular Carcinoma (Biologic)	Phase 2
	PF-05212384	PI3K Inhibitor	Endometrial Cancer, *Cancer	Phase 2
	PD-0325901		Cancer (in combination with PF-05212384)	Phase 1
	PF-03084014		Cancer	Phase 1
	PF-04449913		Acute Myelocytic Leukemia	Phase 1
	PF-05082566		Cancer (Biologic)	Phase 1
	▶ PF-06263507		Cancer	Phase 1

* Note: Additional indications in Phase 1



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Pfizer Pipeline – November 8, 2013 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Vaccines	MnB rLP2086 (PF-05212366)	Prophylactic Vaccine	Adolescent and Young Adult Meningitis B	Phase 3
	4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)	Prophylactic Vaccine	Staph Aureus	Phase 2
	PF-05402536		Smoking Cessation	Phase 1
	PF-06425090		Clostridium Difficile Colitis	Phase 1
	PF-06444752		Asthma	Phase 1

New Molecular Entity



Pfizer Pipeline – November 8, 2013 (cont'd)

New Molecular Entity

New Indication or Enhancement

Biosimilar

Therapeutic Area	Compound Name	Mechanism of Action (Phase 2 through regulatory approval)	Indication	Phase
Other Areas of Focus (Rare Diseases)	tafamidis meglumine	Transthyretin (TTR) Dissociation Inhibitor	Transthyretin familial amyloid polyneuropathy (U.S.)	Registration
	Rivipansel (GMI-1070)	Pan-Selectin Antagonist	Vaso-occlusive crisis associated with Sickle Cell Disease	Phase 2
	▶ PF-05230907		Intracerebral Hemorrhage	Phase 1
	PF-05280602		Hemophilia (Biologic)	Phase 1
	PF-06252616		Muscular Dystrophies (Biologic)	Phase 1
	PF-06687859		Spinal Muscular Atrophy	Phase 1
Other Areas of Focus (Biosimilars)	PF-05280014 (a potential trastuzumab Biosimilar*)		Metastatic Breast Cancer (Biosimilar)	Phase 1
	PF-05280586 (a potential rituximab Biosimilar*)		Rheumatoid Arthritis (Biosimilar)	Phase 1
	PF-06410293 (a potential adalimumab Biosimilar*)		Rheumatoid Arthritis (Biosimilar)	Phase 1
	PF-06438179 (a potential infliximab Biosimilar*)		Rheumatoid Arthritis (Biosimilar)	Phase 1
Other Areas of Focus	Conjugated estrogens/bazedoxifene	Tissue Selective Estrogen Complex	Menopausal Vasomotor Symptoms and Osteoporosis (EU)	Registration
	Viviant	Selective Estrogen Receptor Modulator	Osteoporosis Treatment and Prevention (U.S.)	Registration
	Zithromax/chloroquine	5-OS Ribosome Inhibitor	Malaria	Phase 3
	bosutinib	Abl and src-family kinase Inhibitor	Autosomal Dominant Polycystic Kidney Disease	Phase 2



* Biosimilarity has not yet been established by regulators and is not claimed.

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com